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OBJECTIVES This study was designed to assess outpatient angiotensin-converting enzyme inhibitor
(ACEI) use after heart failure (HF) hospitalization.
BACKGROUND Assuring therapy with ACEIs at discharge after HF hospitalization is a key Medicare quality
measure. The benefits of such quality improvement attempts will be limited if therapy is not
continued long-term.
METHODS To assess the factors associated with filling an ACEI prescription in the 30 days postdischarge
and the proportion of patients who filled such prescriptions subsequently up to 365 days
postdischarge, we studied 219 patients with depressed ejection fraction (EF) specifically and
960 HF patients in general.
RESULTS Sixty-seven percent of patients with depressed EF and 55% of the total cohort were
discharged with ACEIs. Overall 81.2%/77.1% (depressed EF/total cohort) of survivors
discharged with ACEIs had filled a prescription by 30 days postdischarge; only 66.3%/63.3%
were current users at 365 days. In contrast, for patients with no discharge order for ACEIs,
only 12.7%/12.0% (depressed EF/total cohort) had filled such a prescription by 30 days and
12.5%/18.8% were current users at 365 days postdischarge. Patients with a discharge order for
ACEIs were more likely to fill a prescription within 30 days postdischarge (hazard ratio 10.93,
95% confidence interval 5.28, 22.61, for patients with depressed EF).
CONCLUSIONS For patients with HF who are discharged while taking ACEIs, there is a significant decline
in use after discharge. Patients not discharged with ACEIs are unlikely to be started as
outpatients. Quality improvement efforts therefore need to be focused on both discharge
planning and outpatient care. (J Am Coll Cardiol 2004;43:2036–43) © 2004 by the
American College of Cardiology Foundationu
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clinical trials have convincingly demonstrated the benefits
f angiotensin-converting enzyme inhibitor (ACEI) therapy
or heart failure (HF) patients with depressed ejection
raction (EF) (1). Other data suggest potential benefit with
enin-angiotensin system modulation in patients with HF
nd preserved EF also (2). The role of ACEI use in
revention of HF in high-risk patients continues to evolve
3). Finally, many patients with HF also have comorbidities
uch as hypertension and diabetes that may warrant ACEI
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or Education and Research in Therapeutics, Vanderbilt University, Nashville,
ennessee; §Geriatrics Research, Education, and Clinical Center, Nashville VAMC,
ashville, Tennessee; and Centers for Healthcare Quality Inc., Memphis,
ennessee. Supported in part by the Agency for Healthcare Research and Quality,
enters for Education and Research in Therapeutics cooperative agreement (grant
HS 1-0384) and a cooperative agreement with the Food and Drug Administration
FD-U-001641). The analyses upon which this publication is based were performed
nder contract number 500-99-TN01, titled “Quality Improvement Organization for
he State of Tennessee,” sponsored by the Centers for Medicare and Medicaid
ervices, Department of Health and Human Services. The content of this publication
oes not necessarily reflect the views or policies of the Department of Health and
uman Services, nor does mention of trade names, commercial products, or
rganizations imply endorsement by the U.S. Government. The authors assume full
esponsibility for the accuracy and completeness of the ideas presented. This article is
direct result of the Health Care Quality Improvement Program initiated by the
enters for Medicare and Medicaid Services, which has encouraged identification of
uality improvement projects derived from analysis of patterns of care. Ideas and
ontributions to the authors concerning experience in engaging with issues presented
re welcomed.
Manuscript received November 24, 2003; revised manuscript received January 5,
h004, accepted January 13, 2004.se (4,5). Therefore, some experts suggest that ACEIs
hould be used for all HF patients irrespective of EF (6).
The American College of Cardiology and American
eart Association guidelines for HF management recom-
end routine lifelong ACEI therapy, unless contraindi-
ated, for HF patients with depressed EF (7). Clinical use of
hese drugs, however, remains suboptimal (8). Both the
oint Commission for Accreditation of Healthcare Organi-
ations (JCAHO) and Centers for Medicare and Medicaid
ervices (CMS) have selected ACEI use in HF patients
ith depressed EF as a key quality measure for hospitalized
F and myocardial infarction patients (9,10). This has led
o development of many quality improvement interventions
o improve compliance with these quality measures (11,12).
nterest in implementing quality improvement interventions
as become more important recently because JCAHO now
andates the reporting of data on select quality measures
nd CMS is preparing to report quality-of-care data to the
ublic (13).
Medication prescription at discharge, however, does not
uarantee long-term use. Patients may fail to fill prescrip-
ions for discharge medications. Many patients who initially
se these medications may later discontinue their use
ecause of intolerance or poor adherence to recommended
are (7). Thus, quality improvement efforts restricted to
ospitals may not achieve their promised effectiveness.
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June 2, 2004:2036–43 Outpatient Utilization of ACEIsAlthough predictors of ACEI use have been described,
ong-term adherence once therapy is initiated is not well
nown (14–17). We sought to assess the outpatient utili-
ation of ACEI therapy during the first year postdischarge
fter a hospitalization for HF. We also assessed the new use
f ACEI therapy for patients who were not discharged
hile taking them. We identified a population-based cohort
f Medicare beneficiaries discharged alive after being ad-
itted with decompensated HF. The study cohort was that
ubset of patients who were also enrolled in the Tennessee
edicaid Program at discharge and thus eligible to receive
harmacy benefits, which enabled us to determine their use
f ACEIs in the year following discharge.
ETHODS
ources of data. MEDICARE DATA. The Medicare data for
his study came from two different sources. First, CMS
ollected data on 756 random patients from Tennessee from
pril 1, 1998, to September 30, 1998, as part of baseline
ata for the Sixth Scope of Work initiative. Later, Tennes-
ee’s Medicare Quality Improvement Organization col-
ected data on 90 random charts/month on hospitalized
atients with HF across Tennessee from June 1, 1999, to
eptember 30, 2001, in order to provide ongoing feedback
f data to providers over time. Data collection methodology
as similar for both initiatives.
EDICAID DATA. The study was conducted among enroll-
es of the Tennessee Medicaid (TennCare) program. Med-
caid computerized files permitted linkage to the Quality
mprovement Organization data and identification of pre-
criptions filled. The Medicaid pharmacy file contains
eimbursed prescriptions for outpatients and nursing home
esidents. This file identifies the date the prescription was
lled, which specific drug and dose was dispensed, the
umber of pills dispensed, and the number of days of drug
upply (maximum 30 days in Medicaid).
tudy population. A total of 3,174 cases of hospitalized
F patients (756 CMS baseline data for Sixth Scope of
ork and 2,420 Quality Improvement Organization data)
ere identified. A total of 1,617 of these patients (51%)
ere also enrolled in Medicaid at the time of hospital
ischarge and had prescription drug benefits through the
rogram. We excluded 54 patients who were transferred to
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ARB  angiotensin receptor blocker
CMS  Centers for Medicare and Medicaid Services
EF  ejection fraction
HF  heart failure
HR  hazard ratio
JCAHO  Joint Commission for Accreditation of
Healthcare Organizationsnother acute care facility and 63 patients who died during rospitalization. To avoid including patients who may get
etrospective activation of their Medicaid privileges and
ould not have been eligible for medication benefits at
ischarge, we required enrollment for at least 60 days before
ospitalization, leaving 1,059 patients. Although all enroll-
es in Medicaid have access to prescription drugs through
he program, some may choose to use other sources of
rescription medications (e.g., VA hospitals). To assure that
ll study subjects were able to fill a prescription through the
edicaid program, the analysis was restricted to 1,041 of
he remaining patients who filled at least one prescription in
he year before discharge or in the first 30 days postdis-
harge. Finally, 81 of the 1,041 patients in the study cohort
ad documented allergy or intolerance to ACEIs, leaving
he final study cohort of 960 patients. Of these 960 patients,
71, 686, and 550 subjects were alive and enrolled in
edicaid at 30, 180, and 365 days post-HF discharge,
espectively.
uman subjects. This study was approved by Vanderbilt
niversity and the State of Tennessee Institutional Review
oards, and reviewed and approved by the CMS and by the
ennessee Medicaid Program.
ata collections. Details of CMS data collection and
efinitions have been described previously (8). Data collec-
ion by Quality Improvement Organization was similar to
MS methodology. For assessing whether ACEI therapy
as prescribed at discharge or not, the abstractors reviewed
he chart comprehensively, including clinical notes (both
hysician and nursing), physician orders, pharmacy sheets,
nd discharge summaries. The abstractors were provided
ith a list of both generic and trade names of all available
CEIs.
Patients with hypertension and diabetes were identified
y either the specific documentation of these comorbidities
n the data collection tool or coding of specific International
lassification of Diseases-9 codes for these two conditions
n their Medicaid records. Finally, patients who filled
rescriptions for either insulin or other hypoglycemic med-
cations were classified as having diabetes.
Depressed EF was defined either as a quantitative esti-
ate of 40% or a qualitative estimate of at least moderate
ystolic dysfunction. The qualitative EF information was
ollected under the following six categories: 1) normal,
reserved, or satisfactory; 2) mild dysfunction; 3) moderate
r moderate to severe dysfunction, or low function; 4) severe
r very severe dysfunction, or very low or poor function; 5)
ystolic dysfunction, severity not specified; and 6) descrip-
ion not classified in the other categories. For the purpose of
his analysis, only patients in categories 3 and 4 were
lassified as having systolic dysfunction with EF 40%.
ngiotensin-converting enzyme inhibitor intolerance was
efined as documentation by a physician of moderate to
evere aortic stenosis or bilateral renal artery stenosis;
ngioedema, rash, hives, “allergy,” or “adverse reaction”
ssociated with ACEI; or “ACEI intolerance” or other
eason for not prescribing an ACEI.
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Outpatient Utilization of ACEIs June 2, 2004:2036–43Clinical data from the medical records were collected by
ormally trained project data specialists. The data abstrac-
ion tool was piloted on randomly selected HF charts that
ere available from a previous study. The clinical consul-
ant, project data specialists, and analysts used the results
rom the pilot test to refine the abstraction tool. Reliability
as measured using the Project Data Specialist Team
tandard procedures. These include the testing and refine-
ent of data collection tools, educational sessions, and an
ssessment of the consistency of results among the data
pecialists. Inter-rater reliability was assessed with a require-
ent of95% agreement on ACEI use. An internal quality
ontrol process was also conducted using a 5% random
ample. A separate project data collection specialist reab-
tracted these charts and the results were compared to
nsure reliability using similar standards.
utcome. The outcomes studied were the proportion of
atients who filled a prescription for an ACEI within 30
ays after discharge and the proportion that had a current
rescription (filled in the prior 30 days) at 180 and 365 days
ostdischarge. Prescriptions in Medicaid usually may not
xceed 30 days. We also studied the predictors of filling an
CEI prescription by 30 days for all patients and predictors
f outpatient adherence at one year postdischarge among
hose who were discharged while taking ACEIs and filled a
rescription by 30 days. We performed an additional anal-
sis that assessed the use of ACEIs or angiotensin receptor
locker (ARB) therapy, because these latter drugs are often
sed for patients who become intolerant of ACEIs.
tatistical analysis. Descriptive analyses were performed
nd the data were tabulated as means or frequencies.
roportional hazards regression was used to estimate ad-
usted hazard ratios (HR) and 95% confidence intervals (CI)
ssessing patient characteristics related to the time to filling
n ACEI prescription within the first 30 days postdischarge.
he following characteristics were studied as potential
redictors: age (65, 65 to 74, 75), gender, race, admis-
ion and discharge ACEI use, cardiology involvement in
are, EF (preserved, depressed, or missing), and presence of
ypertension or diabetes. We studied the proportion use of
CEI and ACEI or ARB at 30, 180, and 365 days
ostdischarge. However, considering the relatively low use
f ARB, we restricted the analysis of predictors of adherence
o ACEI therapy alone.
To assess the predictors of long-term adherence, we
efined a cohort of patients who were discharged with
CEIs and who filled a prescription for them by 30 days
fter discharge. Similar variables used to assess 30-day
redictors were also studied for 365-day adherence. Logistic
egression was used to calculate adjusted odds ratios and
5% CIs for the relationship of ACEI status at 365 days to
atient characteristics. Odds ratios were converted to rela-
ive risks. Regression diagnostics were performed to assess
he appropriateness of the proportional hazards and logistic
egression models.Because data on cardiology involvement in care and EF aere missing in a large proportion of patients, we did two
ets of analysis to assess predictors of adherence for both 30
nd 365 days post-discharge. In the first set, data on
atients with all predictor variables present were assessed
nd a second analysis was performed excluding provider and
F as variables. There were no significant differences noted
etween the two analyses, so data on only the latter analysis
s presented. Because recommendation for ACEI therapy
or HF patients is more conclusive for patients with de-
ressed EF, we did two sets of analyses, primarily on a on a
ubgroup of HF patients with depressed EF, and second on
he overall cohort. All analyses were performed using SAS
ersion 8.2 (SAS Institute, Cary, North Carolina).
ESULTS
atient characteristics. Overall we studied 960 patients
ho were discharged alive after HF hospitalization and had
o documented intolerance or contraindication for an
CEIs (Table 1). Ejection fraction was depressed in 219
23%) of the 960 patients, was preserved in 265 (28%), and
issing for the rest of the cohort. Hypertension or diabetes
ach was present in almost half of the patients, with a higher
roportion in patients with depressed EF. Sixty-seven
ercent of those with depressed EF and 55% of the overall
ohort were discharged while taking an ACEI. A discharge
rescription for an ACEI was the strongest predictor of
lling a prescription within 30 days for patients with
epressed EF (HR 10.93, 95% CI 5.28, 22.61) and also for
he overall cohort (HR 14.09, 95% CI 8.28, 23.97), after
djusting for patient characteristics listed in Table 1. None
f the other characteristics, including demographics, ACEI
se on admission, cardiology involvement, and presence of
ypertension or diabetes, were independent predictors of
CEI use after discharge.
verall ACEI use. A total of 447 of the 960 patients
47%) were taking ACEIs at admission, including 118 of
19 (54%) of those with depressed EF. Admission with
CEIs was highly associated with discharge prescription of
CEIs. Among patients with depressed EF, 87% of pa-
ients taking ACEIs at admission were discharged with
CEIs, and 44% of patients not taking ACEIs at admission
ere discharged with them (p  0.001). For the overall
ohort, among patients taking ACEIs at admission 89%
ere discharged on ACEI, whereas only 29% of patients not
aking ACEIs at admission were discharged with them (p
.001).
Daily outpatient adherence to ACEI therapy after dis-
harge among patients with depressed EF is shown in
igure 1. Among patients with a documented discharge
rescription for ACEIs, approximately 81% were using
hem during the first 30 days as measured by prescriptions
lled. There was a sharp decline around day 30, which
epresents gaps in prescriptions refilled, followed by an
ncrease and then a gradual decrease that remained at
round 60% to 65% from approximately 90 through 365
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June 2, 2004:2036–43 Outpatient Utilization of ACEIsays. Among patients without a discharge prescription for
CEIs, approximately 10% to 15% were using ACEIs
uring the first 30 days; use plateaued at around 15% to 20%
y day 180. Figure 2 shows the use of ACEIs for the entire
ohort, which shows results similar to those with depressed
F only specifically.
CEI versus ARB use. Only 4% of the 960 study patients
ere discharged with ARB versus 55% with ACEIs. For
atients discharged with ACEIs, 77% were taking ACEIs at
0 days and an additional 1% was taking ARB, whereas at
ne year, 63% were still taking ACEIs and 3% were taking
RB. Of those with no documented discharge order for
CEIs, ACEI use increased modestly over the following
ear from 12% to 19% overall while ARB use remained at
pproximately 8% to 10% (Table 2).
dherence to ACEI use. For patients discharged with an
CEI who filled such a prescription in the first 30 days,
here were no significant associations between the baseline
haracteristics and one-year adherence with ACEI for either
he patients with depressed EF specifically or the overall
able 1. Patient Characteristics Associated With ACEI Prescript
Patient Characteristic
ACEI Use
All Patients (n  960)*
n
% Filled ACEI Prescription
by Day 30 HR
ge (yrs)
65 211 50.2
65–74 295 49.8 1.0
 75 454 46.7 0.8
ace
White 682 46.6
Black 251 53.4 1.2
Other/unknown 27 48.2 1.0
ender
Male 293 47.1
Female 667 49.0 1.0
CEI on admission
No 513 28.9
Yes 447 70.9 0.8
ischarged on ACEI
No 405 11.9
Yes 528 75.8 14.0
ardiology involvement
No 635 49.1
Yes 164 47.6 0.8
jection fraction
Preserved 265 45.3
Depressed 219 58.5 1.2
Missing 476 45.6
ypertension
No 526 46.2
Yes 434 51.2 1.1
iabetes mellitus
No 493 46.3
Yes 467 50.8 0.9
Missing values for discharged on angiotensin-converting enzyme inhibitor (ACEI)
odel consists of 411 patients because of missing data, in particular from provider a
6). §Adjusted for all other variables presented in the table. Model consists of 188 p
CI  confidence interval; HR  hazard ratio.ohort (Table 3). dISCUSSION
espite the benefits of ACEI therapy in patients with HF,
ur study once again documents underutilization of ACEIs
n this relatively contemporaneous cohort of HF patients.
lthough underutilization of ACEI therapy and its predic-
ors has been described before, we also demonstrated that
he use of these agents diminishes further over time after
herapy is initiated, leaving a minority of patients with
ong-term treatment (14–17). In our cohort, the only
ndependent predictor of filling an ACEI prescription as an
utpatient was prescription at the time of discharge. New
se among those not discharged with ACEIs was low,
nderscoring the importance of careful discharge planning.
Suboptimal cardiovascular pharmacotherapy has been
ell described (8). Based on these results, both CMS and
CAHO have designated a combined set of quality mea-
ures for both myocardial infarction and HF, including
CEI use (9,10). Moreover, CMS is now assessing the
ossibility of public disclosure of hospital health care quality
n the First 30 Days Postdischarge
ACEI Use
Low Ejection Fraction Patients (n  219)¶
CI)† n
% Filled ACEI Prescription
by Day 30 HR (95% CI)§
55 65.5 1.0
2, 1.52) 77 59.7 0.82 (0.51, 1.33)
1, 1.28) 87 52.9 0.66 (0.39, 1.09)
141 56.0 1.0
0, 1.60) 73 63.0 1.19 (0.80, 1.76)
6, 2.76) 5 60.0 0.63 (0.15, 2.67)
88 58.0 1.0
6, 1.46) 131 58.8 1.11 (0.74, 1.67)
101 37.6 1.0
1, 1.11) 118 76.3 1.17 (0.77, 1.79)
71 14.1 1.0
8, 23.97) 143 79.7 10.93 (5.28, 22.61)
119 64.7 1.0
6, 1.20) 74 56.8 0.77 (0.52, 1.14)
— — —
4, 1.66) — — —
— — —
119 53.8 1.0
3, 1.44) 100 64.0 1.24 (0.84, 1.82)
124 55.7 1.0
1, 1.23) 95 62.1 0.99 (0.68, 1.46)
7), and provider (n  161). †Adjusted for all other variables presented in the table.
ction fraction. ¶Missing values for discharged on ACEI (n  5), and provider (n 
s.ion i
(95%
1.0
4 (0.7
8 (0.6
1.0
0 (0.9
0 (0.3
1.0
6 (0.7
1.0
2 (0.6
1.0
9 (8.2
1.0
9 (0.6
1.0
5 (0.9
—
1.0
0 (0.8
1.0
3 (0.7
(n  2
nd eje
atientata (13). Such assessments may be used to rate hospitals,
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Outpatient Utilization of ACEIs June 2, 2004:2036–43sually resulting in a significant attention by the popular
ress (18). In response, both professional organizations and
ndividual hospitals are rapidly trying to implement new
ystems to improve compliance with such quality measures
11,12). Although such interventions are commendable, if
he use of these medications is not continued in outpatients,
igure 1. Angiotensin-converting enzyme inhibitor (ACEI) use after d
epressed ejection fraction. Use of ACEI is shown among patients who w
hown from discharge to one year postdischarge and includes patients wh
igure 2. Angiotensin-converting enzyme inhibitor (ACEI) use after disc
imilar to Figure 1 are shown for the total cohort.he potential benefits from these costly interventions are
ikely to be significantly lessened. In this study of patients
ith no documented intolerance to ACEIs, not only were
lmost half of the overall cohort and one-third of those with
epressed EF not prescribed ACEIs, almost one-third of
he patients who were discharged with ACEIs had stopped
rge from hospitalization for decompensated heart failure patients with
nd were not given a prescription for them at discharge. The adherence is
e alive at any given time period.
from hospitalization for patients with decompensated heart failure. Dataischa
ere aharge
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June 2, 2004:2036–43 Outpatient Utilization of ACEIsaking these medications by one year postdischarge. Con-
idering that almost 50% of HF patients are readmitted
ithin six months of discharge, underutilization of ACEIs
oses a significant risk to the patients (19). Moreover, if
utpatient care specifically after discharge correlates with
verall general outpatient care, then the majority of the HF
atients who have not required hospitalization yet are likely
o be receiving suboptimal care also.
Discharge prescription of ACEIs was the single most
mportant predictor of filling an ACEI prescription as an
utpatient, underscoring the importance of careful discharge
lanning. Previous investigations have shown similar corre-
ation with discharge prescription and long-term medica-
ion use (20). We found a strong correlation between ACEI
se at admission and at discharge. Thus, most patients
ischarged with ACEIs may represent a select group of
atients known to be tolerant to these medications. How-
ver, during a HF hospitalization, both the patient and the
amily members are likely to be more responsive to educa-
ion regarding medication use and may be more motivated
o comply with the recommendations given during the acute
hase. Similarly, nurses and doctors may be able to give
ore detailed information in the hospital setting than in the
usy outpatient clinic where provider-patient contact is
sually very limited. Thus, failure to prescribe an ACEI at
ischarge may represent a missed opportunity. Systems to
upport appropriate prescribing in hospital setting may help
ddress this problem. However, even if patients are dis-
harged on appropriate therapy, our and other data suggest
hat adherence continues to deteriorate in the outpatient
etting (21). Therefore, interventions restricted to hospital
ischarge may be beneficial but are likely to be inadequate.
he fluctuation in use seems to stabilize by six months
ostdischarge. Thus, the first three to six months postdis-
harge may be an appropriate target for additional interven-
ions. Besides the discharge prescription, there were no
ther significant predictors of either 30- or 365-day adher-
nce with ACEI therapy. Data on some key variables such
s provider specialty and EF were missing in a substantial
able 2. ACEIs and ARB Use
Ejection
Fraction
Day 30 (n  871)
n ACEI (%) ACEI or ARB (%) n AC
ACEI Therapy P
verall 497 77.1 77.9 409 6
reserved 139 74.8 76.3 125 6
epressed 133 81.2 82.0 112 5
issing 225 76.0 76.4 172 6
ACEI Therapy Not
verall 374 12.0 21.1 277 1
reserved 108 9.3 17.6 88 1
epressed 63 12.7 31.7 37 1
issing 203 13.3 19.7 152 1
CEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor bloumber of patients in our study, however, reducing the power of detecting difference. However, lack of other
redictors also suggests that the use, or lack thereof, of
CEIs is not explainable on the basis of clinical character-
stics alone.
Beyond allergies, tolerability with ACEI therapy is a
ignificant problem and may restrict the use of these drugs.
ide effects such as hyperkalemia, worsening renal function,
nd hypotension may require careful monitoring (22). Dose
djustment and/or changes in other medications may be
ore preferable to discontinuation, given that lower doses
lso significantly improve survival (23). It is difficult to
etermine the causal relationship of cough to ACEI in
ndividual patients; however, a switch to an ARB is a
easonable option for patients with a chronic cough and no
ther clear etiology. Angiotensin receptor blocker therapy
as also been shown to significantly improve outcomes
mong HF patients (24,25). Among our cohort of patients
ischarged with ACEIs, few were started on ARB therapy
hen ACEIs were discontinued. Therefore, side effects and
ntolerance are unlikely explanations for most of the drug
iscontinuations. A higher proportion of patients not dis-
harged on ACEIs filled ARB prescriptions after discharge.
his may represent either provider preference or undocu-
ented/unknown ACEI intolerances during the index hos-
italization. Irrespective of the debate whether ACEI and
RB have comparable benefit or not, the overall use of
ither of the two drugs was still observed in 30% of
atients not discharged on ACEI.
Our study has several limitations. Because of the retro-
pective nature of the study, we do not have the data on
ultiple clinical and laboratory characteristics at discharge
nd tolerability of these medications by patients after
ischarge. We cannot ascertain the degree to which the lack
f adherence is related to the physician- or patient-related
actors in our study. Our patient population was eligible for
oth Medicare and Medicaid benefits. This may represent a
igher risk population and the results may not be general-
zable. Patients dually eligible for Medicare and Medicaid
ay represent a more adverse group from a socioeconomic
80 (n  686) Day 365 (n  550)
) ACEI or ARB (%) n ACEI (%) ACEI or ARB (%)
bed at Discharge
63.6 332 63.3 66.0
63.2 106 54.7 58.5
59.8 92 66.3 69.6
66.3 134 67.9 69.4
ribed at Discharge
25.3 218 18.8 28.4
26.1 70 12.9 28.6
27.0 32 12.5 25.0
24.3 116 24.1 29.3Day 1
EI (%
rescri
1.6
0.0
8.0
5.1
Presc
7.7
7.0
6.2
8.4erspective. Moreover, these patients are likely to be older,
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Outpatient Utilization of ACEIs June 2, 2004:2036–43ess well educated, may more often belong to a racial or
thnic minority, and may have poor access to care. However,
atients enrolled in Medicaid were a significant proportion
f all Medicare patients with HF hospitalizations (50%)
n our state, and thus are likely to be not too dissimilar to
he general Medicare population. In addition, these patients
ave prescription pharmacy benefits, which remove the finan-
ial barrier to obtaining their medications. Our overall sample
ize is relatively small. Finally, in our study cardiology involve-
ent in care included any interaction with a cardiologist during
ospitalization, either in consultation or as a primary service.
e have no data on whether cardiology was involved in the
utpatient care. Thus, the influence of physician specialty on
CEI adherence cannot be assessed for certain.
In order to maximize patient outcomes after hospitaliza-
ion for HF, attempts must be made to improve upon
urrent trends. Multiple interventions directed at patients
ave been shown to increase adherence with medications
26). Other investigators have described the hospital-related
actors that were associated with quality improvement with
harmacotherapy at hospital discharge (27). Prospective
tudies are needed to assess the effectiveness, safety, and
Table 3. Patient Characteristics and ACEI Ad
Postdischarge
Patient Characteristic
Patients With Low
(n  70)
RR (95% CI)
On ACEI, N (%) 46 (66%)
Age (yrs)
65 1.0
65–74 0.69 (0.29, 1.09
 75 0.81 (0.36, 1.18
Race
White 1.0
Black 1.05 (0.60, 1.38
Other‡ —
Gender
Male 1.0
Female 1.24 (0.85, 1.46
Cardiology involvement
No 1.0
Yes 0.70 (0.35, 1.04
Ejection fraction
Preserved —
Depressed —
ACEI at admission
No 1.0
Yes 0.77 (0.33, 1.22
Hypertension
No 1.0
Yes 0.94 (0.55, 1.25
Diabetes mellitus
No 1.0
Yes 1.05 (0.64, 1.33
Restricted to patients alive at 365 days postdischarge, disch
filled a prescription for ACEI within 30 days postdischarge
table. *Model does not adjust for provider and ejection fraction
Reduced number of patients is due to missing data in provid
1 patient of other race and was excluded.
CI  confidence interval; RR  relative risk.olerability of these drugs in patients who are at a higher riskor side effects. However, because lower doses are associated
ith significant survival benefit, patients with relative intol-
rance should at least be tried on smaller doses if larger
oses are not tolerated (23).
In conclusion, our study suggests that a significant pro-
ortion of patients who are discharged with ACEI therapy
o not fill their prescription as outpatients. Discharge
dministration of ACEIs is the strongest predictor of
ontinued use. The use of these drugs is less than optimal in
ll groups of patients, based on demographics and clinical
haracteristics. New outpatient prescriptions for those not
ischarged with ACEI therapy is infrequent. Quality im-
rovement efforts should focus on improving discharge
lanning and preferably should continue up to six months
ostdischarge.
eprint requests and correspondence: Dr. Javed Butler, Cardi-
logy Division, 383-PRB, Vanderbilt University Medical Center,
ashville, Tennessee 37232. E-mail: javed.butler@vanderbilt.edu.
EFERENCES
1. Garg R, Yusuf S. Overview of randomized trials of angiotensin-
ce Among Surviving Patients at 365 Days
All Patients
(n  253)*
RR (95% CI)
All Patients
(n  140)†
RR (95% CI)
170 (67%) 88 (63%)
1.0 1.0
0.96 (0.71, 1.18) 0.78 (0.43, 1.12)
1.00 (0.76, 1.20) 0.85 (0.48, 1.17)
1.0 1.0
0.90 (0.71, 1.07) 0.77 (0.51, 1.02)
0.86 (0.27, 1.29) 0.82 (0.09, 1.37)
1.0 1.0
1.10 (0.89, 1.28) 1.24 (0.96, 1.42)
— 1.0
— 0.79 (0.50, 1.05)
— 1.0
— 1.16 (0.91, 1.31)
1.0
1.07 (0.77, 1.29)
1.0 1.0
0.97 (0.79, 1.13) 0.95 (0.69, 1.17)
1.0 1.0
1.02 (0.84, 1.16) 1.01 (0.77, 1.20)
ith angiotensin-converting enzyme inhibitor (ACEI), and
53). Adjusted for other all other variables presented in the
. †Model adjusts for all other variables presented in the table.
EF. ‡After restrictions in the low EF group, there was onlyheren
EF
)
)
)
)
)
)
)
)
arged w
(n  2
(EF)
er andconverting enzyme inhibitors on mortality and morbidity in patients
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2043JACC Vol. 43, No. 11, 2004 Butler et al.
June 2, 2004:2036–43 Outpatient Utilization of ACEIswith heart failure. Collaborative Group on ACE Inhibitor Trials.
JAMA 1995;273:1450–6.
2. Yusuf S, Pfeffer MA, Swedberg KS, et al. Effects of candesartan in
patients with chronic heart failure and preserved left-ventricular
ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777–
81.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of
an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascu-
lar events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med 2000;342:145–53.
4. Clark MJ Jr., Sterrett JJ, Carson DS. Diabetes guidelines: a summary
and comparison of the recommendations of the American Diabetes
Association, Veterans Health Administration, and American Associ-
ation of Clinical Endocrinologists. Clin Ther 2000;22:899–910.
5. Aram V, Chobanian GL, Henry R, et al. The Seventh Report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC 7 Report. JAMA
2003;289:2560–71.
6. Konstam MA. Systolic and diastolic dysfunction in heart failure? Time
for a new paradigm. J Card Fail 2003;9:1–3.
7. Hunt SA, Baker DW, Chin M, et al. ACC/AHA guidelines for the
evaluation and management of chronic heart failure in the adult:
executive summary. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines.
Circulation 2001;104:2996–3007.
8. Jencks SF, Cuerdon T, Burwen D, et al. Quality of medical care
delivered to Medicare beneficiaries: a profile at state and national
levels. JAMA 2000;284:1670–6.
9. JCAHO Overview of Heart Failure Core Measure Set. Available at:
http://www.jcaho.org/pms/coremeasures/hf_overview.htm. Ac-
cessed June 16, 2003.
0. Quality Improvement Organizations: Statement of Work. Available
at: http://cms.hhs.gov/qio/2.asp. Accessed June 16, 2003.
1. Get With The Guidelines. American Heart Association. Available at:
http://www.americanheart.org/presenter.jhtml?identifier1165. Ac-
cessed June 16, 2003.
2. Guidelines Applied in Practice. American College of Cardiology.
Available at: http://www.acc.org/gap/gap. Accessed June 16, 2003.
3. Hospital Quality Information Initiative. Available at: http://
www.cms.hhs.gov/quality/hospital/hqii.asp. Accessed June 16, 2003.
4. Stafford RS, Saglam D, Blumenthal D. National patterns of
angiotensin-converting enzyme inhibitor use in congestive heart fail-
ure. Arch Intern Med 1997;157:2460–4.5. Philbin EF, Andreaou C, Rocco TA, et al. Patterns of angiotensin-
converting enzyme inhibitor use in congestive heart failure in two
community hospitals. Am J Cardiol 1996;10:832–8.
6. The Large State Peer Review Organization Consortium. Heart failure
treatment with angiotensin-converting enzyme inhibitors in hospital-
ized Medicare patients in 10 large states. Arch Intern Med 1997;157:
1103–8.
7. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of
appropriate use of angiotensin-converting enzyme inhibitors after
acute myocardial infarction in persons 65 years of age. Am J Cardiol
1997;79:581–6.
8. Best Hospitals. Available at: http://www.usnews.com/usnews/nycu/
health/hosptl/ranking. Accessed June 16, 2003.
9. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospital-
ization for congestive heart failure among Medicare beneficiaries. Arch
Int Med 1997;157:99–104.
0. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to
beta-blocker therapy after acute myocardial infarction. J Am Coll
Cardiol 2002;40:1589–95.
1. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-
lowering medications: a cross-national study. JAMA 1998;279:
1458–62.
2. Bradley A, Bart MD, Gattis WA, Diem SJ, O’Connor CM. Reasons
for underuse of angiotensin-converting enzyme inhibitors in patients
with heart failure and left ventricular dysfunction. Am J Cardiol
1997;79:1118–20.
3. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative
effects of low and high doses of the angiotensin-converting enzyme
inhibitor, lisinopril, on morbidity and mortality in chronic heart
failure. ATLAS Study Group. Circulation 1999;100:2312–8.
4. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A
randomized trial of the angiotensin-receptor blocker valsartan in
chronic heart failure. N Engl J Med 2001;345:1667–75.
5. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared
with captopril on mortality in patients with symptomatic heart failure:
randomised trial—the Losartan Heart Failure Survival Study, ELITE
II. Lancet 2000;355:1582–7.
6. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC,
Kanani R. Interventions for helping patients to follow prescription
medications. Cochrane Database Systematic Revs 2001;3:1–34.
7. Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ,
Krumholz HM. A qualitative study of increasing beta-blocker use after
myocardial infarction. Why do some hospitals succeed? JAMA 2001;
285:2604–11.
